---
title: "RR.: Raised FY26 guidance after strong H1 growth in profit, cash flow, and all core divisions"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294312156.md"
description: "Strong first half results with revenue up 26% and operating profit up 46% year-over-year, driven by transformation and growth across all divisions. FY26 guidance for operating profit and free cash flow was raised, with continued strategic progress and robust capital returns.Original document: Rolls-Royce Holdings plc [RR.] Slides Release — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T06:26:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294312156.md)
  - [en](https://longbridge.com/en/news/294312156.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294312156.md)
generator: "portal-rs"
---

# RR.: Raised FY26 guidance after strong H1 growth in profit, cash flow, and all core divisions

Strong first half results with revenue up 26% and operating profit up 46% year-over-year, driven by transformation and growth across all divisions. FY26 guidance for operating profit and free cash flow was raised, with continued strategic progress and robust capital returns.

Original document: Rolls-Royce Holdings plc \[RR.\] Slides Release — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [RYCEY.US](https://longbridge.com/en/quote/RYCEY.US.md)
- [RR.UK](https://longbridge.com/en/quote/RR.UK.md)

## Related News & Research

- [BFT: Double-digit EBIT growth, margin expansion, and strong cash flow drive robust 2Q26 results](https://longbridge.com/en/news/296514233.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)
- [ZOOM: Q2 2026 saw strong sales growth, positive EBIT, and robust financial strengthening](https://longbridge.com/en/news/296636864.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**